Probability of deceased donor kidney transplantation based on % PRA

Transplant Immunology

Volumn 28, Issue 4, 2013, Pages 154-158

  Bostock, I C ^a   Alberu J ^a   Arvizu, A ^a   Hernandez Mendez E A ^a   De Santiago, A ^a   Gonzalez Tableros N ^a   Lopez M ^a   Castelan N ^a   Contreras, A G ^a   Morales Buenrostro, L E ^a   Gabilondo, B ^a   Vilatoba M ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Deceased donor kidney transplantation; Highly sensitized; Kidney transplant recipient; Panel reactive antibody; Sensitization

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANEL REACTIVE ANTIBODY; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BLOOD GROUP ABO SYSTEM; FEMALE; GRAFT RECIPIENT; HLA TYPING; HOSPITAL ADMISSION; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; CADAVER; DONOR; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; PROBABILITY; STATISTICS AND NUMERICAL DATA;

ADULT; CADAVER; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; KIDNEY TRANSPLANTATION; MALE; PROBABILITY; TISSUE DONORS; WAITING LISTS;

EID: 84879843726     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2013.05.002     Document Type: Article

References (23)

1. Marfo K., Lu A., Ling M., et al. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011, 6:922-936. 10.2215/CJN.08140910.
2. Jordan S.C., Pescovitz M.D. Presensitization: the problem and its management. Clin J Am Soc Nephrol 2006, 1:421-432. 10.2215/CJN.01651105.
3. Port F.K., Wolfe R.A., Mauger E.A., et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993, 270:1339-1343.
4. Russell J.D., Beecroft M.L., Ludwin D., et al. The quality of life in renal transplantation-a prospective study. Transplantation 1992, 54:656-660.
5. Wolfe R.A., Ashby V.B., Milford E.L., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999, 341:1725-1730.
6. Organ Procurement Transplantation Network/Scientific Registry of Transplant Recipients: 2004. Annual Report: transplant data 1994-2003 2004, Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; United Network for Organ Sharing; University Renal Research and Education Association.
7. Jordan S., Cunningham-Rundles C., McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003, 3:653-664.
8. (Accessed March 5th, 2013). http://www.cenatra.salud.gob.mx/descargas/contenido/trasplante/Estado_Actual_2012.pdf.
9. US Renal Data System: USRDS 2003 annual data report. Atlas of end-stage renal diseases in the United States 2003, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda.
10. Ramirez Cruz M.I., Salgado A.A., Morales-Buenrostro L.E., et al. Hyperactue rejection of kidney transplant in the absence of HLA and MICA donor specific antibodies in a patient with lupus nephropathy. Rev Argent Trasplantes 2010, 1:28-34.
11. Racusen L.C., Solez K., Colvin R.B., et al. The Banff '97 working classification of renal allograft pathology. Kidney Int 1999, 55:713.
12. Racusen L.C., Colvin R.B., Solez K., et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003, 3:708.
13. Racusen L.C., Halloran P.F., Solez K., et al. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004, 4:1562.
14. Solez K., Colvin R.B., Racusen L.C., et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007, 7:518.
15. Solez K., Colvin R.B., Racusen L.C., et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008, 4:753.
16. Sis B., Mengel M., Haas M., et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010, 10:464.
17. Mengel M., Sis B., Haas M., et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012, 3:563.
18. Sellarés J., de Freitas D.G., Mengel M., et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012, 12:388.
19. Dunn T.B., Noreen H., Gillingham K., et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011, 11(10):2132-2143.
20. Opelz G., Döhler B. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation 2008, 85(5):661-666. 10.1097/TP.0b013e3181661695.
21. Sijpkens Y.W., Doxiadis I.I., Mallat M.J., et al. Early versus late acute rejection episodes in renal transplantation. Transplantation 2003, 75(2):204-208.
22. Joseph J.T., Kingsmore D.B., Junor B.J., et al. The impact of late acute rejection after cadaveric kidney transplantation. Clin Transplant 2001, 15(4):221-227.
23. Fuggle S.V., Martin S. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation 2008, 86(3):384-390. 10.1097/TP.0b013e31817c90f5.